It is now time for this Editor-in-Chief to disappear around a turn in the road. In saying farewell, I enthusiastically welcome our new Editor-in-Chief, Professor Mamoru Watanabe,
of whom more will be written in the first issue of volume 28 (January 2013). In this exceptionally talented, experienced and hardworking man, the current team of excellent editors, and with you, the informed readers and contributing authors, JGH is in good hands! “
“Background and Aims: selleckchem The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor can enhance endothelial nitric oxide synthase expression and induce vasodilatation. The vasodilatory effect may be detrimental to portal-systemic collaterals due to aggravating the shunting degrees. The present study investigated the effects of pravastatin, a HMG-CoA reductase inhibitor, on the collateral vascular responsiveness to endothelin-1 (ET-1) and portal-systemic shunting in portal hypertensive rats. Methods: AG-014699 manufacturer The partial portal vein-ligated (PVL) rats received either pravastatin (25 mg/kg per day) or distilled water since 2 days prior to until 7 days after ligation. On the 8th day following hemodynamic measurements, the collateral vascular responsiveness to
ET-1 was evaluated by an in situ collateral perfusion model. The shunting degrees of collaterals were evaluated by constructing vascular flow-pressure curves and color microsphere study, respectively. PVL rats underwent pre-incubation with: (i) Krebs solution (control); or Krebs solution plus (ii) 2 × 10−5 M pravastatin; (iii) pravastatin + Nω-nitro-L-arginine (10−4 M); and (iv) pravastatin + indomethacin (10−5 M), followed by ET-1 (10−10–10−7 M) administration to evaluate the collateral vascular responsiveness. Results: In chronic study, pravastatin did not modify systemic and portal hemodynamics and collateral
vascular responsiveness to ET-1. The resistances of flow-pressure curves and the microsphere study demonstrated similar shunting degrees between both groups. Furthermore, pravastatin pre-incubation didn’t reduce collateral perfusion pressure to ET-1. Conclusion: Chronic pravastatin medchemexpress administration does not induce detrimental effects on hemodynamics and collaterals in PVL rats, nor does it influence the shunting degree. In addition, it does not modify the vasoconstrictive effect of ET-1 on the collaterals of PVL rats. “
“Programmed death-1 (PD-1)/B7-H1 costimulation acts as a negative regulator of host alloimmune responses. Although CD4 T cells mediate innate immunity-dominated ischemia and reperfusion injury (IRI) in the liver, the underlying mechanisms remain to be elucidated. This study focused on the role of PD-1/B7-H1 negative signaling in liver IRI.